Methods and compositions for identifying increased risk of developing fragile X-associated disorders
The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1.
1. A method of detecting an ASFMR1e mRNA transcript in a sample from a subject, comprising:
a) obtaining a nucleic acid sample from the subject;
b) assaying the nucleic acid sample for an ASFMR1e mRNA transcript having a cDNA sequence comprising the nucleotide sequence of SEQ ID NO:5; and
c) detecting the ASFMR1e mRNA transcript in the sample.
2. A method of detecting the presence or absence of an ASFMR1e mRNA transcript having a cDNA sequence comprising the nucleotide sequence of SEQ ID NO:5 in a sample from a subject, comprising:
a) obtaining a nucleic acid sample from the subject;
b) contacting the nucleic acid sample with a primer pair consisting of a forward primer comprising the nucleotide sequence of SEQ ID NO:31 and a reverse primer comprising the nucleotide sequence of SEQ ID NO:32 or a primer pair consisting of a forward primer, comprising the nucleotide sequence of SEQ ID NO:29 and a reverse primer comprising the nucleotide sequence of SEQ ID NO:32 , under conditions wherein nucleic acid amplification can occur; and
c) analyzing an amplification product of step (b), thereby detecting the presence or absence of the ASFMR1e mRNA transcript in the sample.